AcuCort AB (publ) (XSAT:ACUC)

Market Cap	213.34M +164.0%
Revenue (ttm)	8.63M +23.0%
Net Income	-26.93M
EPS	-0.16
Shares Out	234.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	915,143
Average Volume	918,625
Open	0.8600
Previous Close	0.8560
Day's Range	0.8290 - 0.9200
52-Week Range	0.5000 - 0.9820
Beta	1.37
RSI	80.26
Earnings Date	Feb 20, 2026

About AcuCort AB

AcuCort AB (publ) operates as a pharmaceutical company. It offers Zeqmelit, an oral film containing the glucocorticoid dexamethasone for the treatment of acute allergic reactions, croup in children, nausea and vomiting associated with chemotherapy, and for the treatment of patients with COVID-19 who experience respiratory difficulties and require oxygen therapy. The company was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 4
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: ACUC

Financial Performance

In 2024, AcuCort AB's revenue was 7.72 million, an increase of 17.07% compared to the previous year's 6.59 million. Losses were -17.40 million, 27.1% more than in 2023.